EMEA-000499-PIP04-17

Key facts

Active substance
Veliparib
Therapeutic area
Oncology
Decision number
P/0063/2018
PIP number
EMEA-000499-PIP04-17
Pharmaceutical form(s)
  • Capsule, hard
  • Age-appropriate oral liquid dosage form
  • Tablet
Condition(s) / indication(s)
Treatment of lung carcinoma (small cell and non-small cell carcinoma)
Route(s) of administration
Oral use
Contact for public enquiries
AbbVie Ltd

E-mail: paediatricteam@abbvie.com
Tel. +44 (0)1628 925033

Decision type
W: decision granting a waiver in all age groups for all conditions/indications

Decision

How useful was this page?

Add your rating